TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioNTech SE ( (BNTX) ) has provided an update.
On November 3, 2025, BioNTech SE announced its third-quarter financial results, highlighting a revenue increase to €1.5 billion, despite a net loss of €28.7 million. The company reported progress in its oncology strategy, particularly with the bispecific antibody candidate pumitamig, and launched a variant-adapted COVID-19 vaccine for the 2025/2026 season. BioNTech also raised its full-year revenue guidance to €2.6-2.8 billion, supported by a $1.5 billion payment from its partnership with Bristol Myers Squibb.
The most recent analyst rating on (BNTX) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech SE’s overall stock score reflects a balance of strengths and challenges. The company’s strong balance sheet and strategic collaborations are positive, but profitability and cash flow issues, along with valuation concerns, weigh on the score.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a biotechnology company based in Mainz, Germany, known for its work in developing mRNA-based vaccines and therapies. The company focuses on oncology and infectious diseases, with significant efforts in cancer immunotherapies and COVID-19 vaccines.
Average Trading Volume: 865,666
Technical Sentiment Signal: Sell
Current Market Cap: $24.98B
For detailed information about BNTX stock, go to TipRanks’ Stock Analysis page.